These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 24288014)

  • 21. Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.
    Nakashima Y; Miyahara H; Kondo M; Fukuda T; Harada H; Haraguchi A; Inoue Y; Ishinishi T; Maekawa M; Maeyama A; Nakashima M; Shono E; Suematsu E; Shimauchi T; Tsuru T; Tsukamoto H; Yoshizawa S; Yoshizawa S; Iwamoto Y
    Mod Rheumatol; 2017 Jan; 27(1):15-21. PubMed ID: 27142240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
    Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
    Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
    Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
    Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
    Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
    Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.
    Nawata M; Saito K; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2008; 18(5):460-4. PubMed ID: 18535759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
    Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
    Mod Rheumatol; 2012 Nov; 22(6):814-22. PubMed ID: 22270346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study.
    Cai YM; Li R; Ye H; He J; Sun XL; Jin JY; Liu JJ; Gan YZ; You XJ; Xu J; Shi LJ; Cheng G; Wang QW; Li ZG
    Chin Med J (Engl); 2020 Jun; 133(12):1397-1403. PubMed ID: 32496302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
    Lee JS; Oh JS; Hong S; Kim YG; Lee CK; Yoo B
    Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
    Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
    Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
    Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
    Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Hiramatsu K; Takeuchi T
    RMD Open; 2016; 2(1):e000189. PubMed ID: 26925252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.